Opinion
New weight loss drugs raise questions of access, costs
New, popular injectable weight loss drugs — GLP-1 drugs — are highly effective at reducing obesity and, probably, the health risks posed by obesity. Yet the drugs are so expensive that insurers are often choosing between two bad options: restricting access or raising consumer costs.
Drugs such as Novo Nordisk’s Ozempic can cut drug and alcohol abuse by up to 50%, a study found, adding to mounting evidence ...
10hon MSN
Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United ...
News Medical on MSN1d
Expanding access to GLP-1 weight-loss drugs could save thousands of livesResearchers estimate that expanding access to weight-loss drugs could save over 50,000 lives annually, reducing obesity rates ...
U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...
Unemployed people living with obesity could be given new weight loss jabs to help them get back into work, the health ...
If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback